Scientists have developed a new method to study the proteins released by cells, which could lead to the development of new tools to track diseases including cancer.
List view / Grid view
Imperial College London
Victoria Rees and Ria Kakkad from Drug Target Review bring you the key takeaways from the ELRIG Drug Discovery 2022 event in London.
UK researchers have created a metal-based molecule that inhibits the build-up of Alzheimer’s-associated peptide, amyloid-β, in lab tests.
A new artificial intelligence (AI) method has been created to uncover which proteins enable bacteria to infect human intestines.
Biliverdin attaches to a region of the SARS-CoV-2 Spike protein, stabilising it so that it is not able to expose its structure to antibodies, a new study has shown.
The multiple serotypes of rhinovirus have presented difficulties for vaccine developers. Now, a team led by Professor Gary McLean from London Metropolitan University and Imperial College London, alongside Professor Sebastian Johnston from Imperial, has formulated a potential vaccine. Nikki Withers spoke to McLean to discover how the vaccine works and…
The UK Government will give £18.5 million in funding to four studies researching the causes and potential treatments of long COVID.
A better understanding of the role of four-stranded DNA (G-quadruplex) could enhance cancer therapeutics, said the developers of the probes.
A total of 21 COVID-19 research projects have been granted funding by the UK government, including vaccine and therapeutic development.
A study has revealed that activation of syndecan-4 sensory protrusions extending from cells may be a future target for cancer therapy.
A new mechanism by which cancer cells become resistant to chemotherapy has been found which could lead to a new target for drugs.
New antibiotics could be designed by discovering the mechanism a weapon bacteria uses to vanquish their competitors.
A new study shows that using therapeutic antibodies to block the interleukin-11 protein can reverse idiopathic pulmonary fibrosis.
Scientists have shown that drug-resistant bacteria infections shut out antibiotics by closing tiny doors in their cell walls.